<DOC>
	<DOCNO>NCT00502905</DOCNO>
	<brief_summary>Primary Objectives : 1 . To administer multiple dos intravenous formulation busulfan ( Bu ) dose adjust yield blood drug level median daily area plasma concentration curve ( AUC ) approximately 6,500 ÂµMol-min . This dose give intravenously three hour daily four ( 4 ) day , combination Fludarabine dose 40 mg/m2 preparation bone marrow peripheral stern cell transplantation patient acute myeloid leukemia myelodysplastic syndrome . 2 . To determine outcome Acute Myeloid Leukemia ( AML ) /myelodysplastic syndrome ( MDS ) patient undergo treatment regimen . Data regard engraftment , toxicity , relapse rate , long-term ( disease-free ) outcome , overall survival collect . 3 . To determine safety profile regimen utilized preparation allogeneic transplantation . 4 . To describe plasma pharmacokinetics busulfan administer intravenously regimen .</brief_summary>
	<brief_title>Busulfan Fludarabine Patients With AML MDS</brief_title>
	<detailed_description>Patients agree optional pharmacology procedure # 1 initially receive therapeutic test dose busulfan test blood level time ; information use determine subsequent high-dose busulfan dos . Patients agree optional pharmacology procedure receive fix dose busulfan previously do 3 year . Patients study receive fludarabine central venous catheter one hour , day , four day . High-dose Busulfan inject catheter three hour , day , four day , start immediately fludarabine . After two day rest , allogeneic bone marrow , peripheral blood stem cell cord blood give intravenously . Patients receive drug Granulocyte colony-stimulating factor ( G-CSF - Neupogen ) injection skin blood count recover . Patients remain hospital 4-6 week . After discharge , patient continue outpatient hospital area able safely leave immediate hospital area minimum 100 day transplant . Some patient may need receive spinal tap instillation cytosine arabinoside hydrocortisone several time year transplantation . This patient previous clinical history leukemic involvement brain . This investigational study . The FDA approve study drug . Up 200 patient take part study . All enrol M. D. Anderson .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>1 . Acute leukemia past first remission , first subsequent relapse , first remission ( highrisk , i.e. , cytogenetics ( 8 ; 21 , inv 16 , ( 15 ; 17 ) ) induction failure . 2 . Myelodysplastic syndrome clinical stage , exclude patient isolated stable monocytopenia clinically stable . 3 . Patient administer systemic chemotherapeutic drug ( include Mylotarg ) within 21 day prior trial enrollment ( BMT Day 7 BMT day 9 ) . ( Hydroxyurea intrathecal chemotherapy permit ) . 4 . No uncontrolled infection . 5 . Patients age 65 eligible study . 6 . ALLOGENEIC TRANSPLANTATION : Patients acceptable related unrelated volunteer donor available bone marrow peripheral blood progenitor cell cord blood transplant . Bone marrow peripheral blood cell donor match least 5 6 HLA A , B DR locus . Cord blood donor match least 4 6 A , B DR locus . 7 . Life expectancy severely limit . 8 . Pulmonary , cardio , renal liver function test normal . 9 . In patient &lt; 7 year pulmonary function assess per pediatric BMT routine . 10 . No evidence chronic active hepatitis cirrhosis . 11 . HIVnegative . 12 . Female patient pregnant 13 . Signed informed consent . 14 . Patient admit Sunday , Monday allow pharmacokinetic directed therapy . 1 ) Not fulfil eligibility criterion .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>66 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Acute Myeloid Leukemia</keyword>
	<keyword>Myelodysplastic Syndromes</keyword>
	<keyword>Busulfan</keyword>
	<keyword>Busulfex</keyword>
	<keyword>Myleran</keyword>
	<keyword>Fludarabine</keyword>
	<keyword>Fludarabine Phosphate</keyword>
	<keyword>Fludara</keyword>
</DOC>